trending Market Intelligence /marketintelligence/en/news-insights/trending/nL0jHfO7GvV8ViCo-D1WJA2 content esgSubNav
In This List

Innovation Pharmaceuticals halts skin drug development after trial fail

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Innovation Pharmaceuticals halts skin drug development after trial fail

Innovation Pharmaceuticals Inc. discontinued the development of its psoriasis drug Prurisol after the therapy failed to show adequate efficacy in a mid-stage trial.

The phase 2b study was evaluating Prurisol in moderate-to-severe chronic plaque psoriasis, an autoimmune disease that causes raised, red, scaly patches to appear on the skin. Prurisol failed to meet its efficacy goals in both 300-milligram and 400-milligram doses as measured by the Psoriasis Area and Severity Index scale, the company said in a filing.

While the Beverly, Mass.-based company plans additional analysis of Prurisol data, Innovation said it is focusing instead on development efforts on its clinical assets Kevetrin and Brilacidin.

Kevetrin is a therapy for ovarian cancer while Brilacidin is a treatment for oral mucositis, or mouth sores — a common complication of cancer treatments.

Meanwhile, Krishna Menon resigned as a director of the company. Innovation said the resignation is not a result of any disagreement with the company.